Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

医学 安慰剂 SOD1 肌萎缩侧索硬化 不利影响 随机化 内科学 置信区间 脑脊液 药代动力学 临床终点 危险系数 麻醉 胃肠病学 临床试验 病理 替代医学 疾病
作者
Jonathan S. Mill,Merit Cudkowicz,Pamela J. Shaw,Peter Munch Andersen,Nazem Atassi,Robert C. Bucelli,Angela L. Genge,Jonathan D. Glass,Shafeeq S. Ladha,Albert Ludolph,Nicholas John Maragakis,Christopher J. McDermott,Alan Pestronk,John Ravits,François Salachas,Randall Trudell,Philip Van Damme,Lorne H. Zinman,C. Frank Bennett,Roger M. Lane
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:383 (2): 109-119 被引量:562
标识
DOI:10.1056/nejmoa2003715
摘要

BACKGROUND: mutations. METHODS: mutations. In each dose cohort (20, 40, 60, or 100 mg), participants were randomly assigned in a 3:1 ratio to receive five doses of tofersen or placebo, administered intrathecally for 12 weeks. The primary outcomes were safety and pharmacokinetics. The secondary outcome was the change from baseline in the cerebrospinal fluid (CSF) SOD1 concentration at day 85. Clinical function and vital capacity were measured. RESULTS: A total of 50 participants underwent randomization and were included in the analyses; 48 participants received all five planned doses. Lumbar puncture-related adverse events were observed in most participants. Elevations in CSF white-cell count and protein were reported as adverse events in 4 and 5 participants, respectively, who received tofersen. Among participants who received tofersen, one died from pulmonary embolus on day 137, and one from respiratory failure on day 152; one participant in the placebo group died from respiratory failure on day 52. The difference at day 85 in the change from baseline in the CSF SOD1 concentration between the tofersen groups and the placebo group was 2 percentage points (95% confidence interval [CI], -18 to 27) for the 20-mg dose, -25 percentage points (95% CI, -40 to -5) for the 40-mg dose, -19 percentage points (95% CI, -35 to 2) for the 60-mg dose, and -33 percentage points (95% CI, -47 to -16) for the 100-mg dose. CONCLUSIONS: mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks. CSF pleocytosis occurred in some participants receiving tofersen. Lumbar puncture-related adverse events were observed in most participants. (Funded by Biogen; ClinicalTrials.gov number, NCT02623699; EudraCT number, 2015-004098-33.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wy完成签到,获得积分10
刚刚
1秒前
Lucas的应助被JANE采纳,获得10
2秒前
布林发布了新的文献求助10
2秒前
May完成签到 ,获得积分10
2秒前
小壶椰椰发布了新的文献求助30
2秒前
烟花的应助被YJ采纳,获得10
2秒前
1111完成签到,获得积分10
2秒前
YAYING发布了新的文献求助10
3秒前
4秒前
4秒前
5秒前
6秒前
6秒前
AXQ发布了新的文献求助50
7秒前
zhengyao完成签到,获得积分20
8秒前
香蕉觅云的应助被WPY采纳,获得10
9秒前
打打的应助被lawang采纳,获得10
9秒前
10秒前
整齐的萝完成签到,获得积分20
10秒前
默默千风发布了新的文献求助10
10秒前
10秒前
Ma关闭了Ma的文献求助
10秒前
11秒前
black_cavalry发布了新的文献求助20
11秒前
粥vbbb发布了新的文献求助10
11秒前
111发布了新的文献求助10
11秒前
WHr完成签到,获得积分10
11秒前
务实的寒凝的应助被aaa采纳,获得10
12秒前
重击老大完成签到,获得积分10
13秒前
14秒前
Csy发布了新的文献求助10
15秒前
无花果的应助被zmang采纳,获得10
17秒前
18秒前
19秒前
pipa_lemon完成签到,获得积分10
19秒前
彭于晏的应助被XiongJiuJiu采纳,获得10
19秒前
欢呼蓝天完成签到,获得积分10
20秒前
Tao发布了新的文献求助10
21秒前
柳七完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192141
求助须知:如何正确求助?哪些是违规求助? 9578771
关于积分的说明 21861764
捐赠科研通 7791657
什么是DOI,文献DOI怎么找? 3436846
关于科研通互助平台的介绍 2560547
邀请新用户注册赠送积分活动 2483605